Discuss BPC-157 on glp1chat
Join the forum to discuss research with other members.
BPC-157: what it is and how it may work
In rat studies, BPC-157 helped injured tendons heal faster and regain strength. It increased collagen—the strong fibers that hold tendons together—and helped small blood vessels grow, bringing more blood to damaged tissue. Other studies found lower signs of inflammation and a short period of reduced pain sensitivity. In simple terms, it supports repair by helping the body rebuild tissue, improve blood supply, and calm the injury response.
A tendon is the strong cord that connects muscle to bone, so repair needs both new supporting fibers and a blood supply. Researchers have also studied BPC-157 in stomach and intestinal injury models, which are separate from the tendon experiments. Its name alone does not tell us whether a different preparation will behave the same way.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Reported findings involve gastrointestinal and musculoskeletal injury models, alongside limited human observations. The formulation, route and study quality must be checked before comparing these results.[1][3][6]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of BPC-157.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 24 units (0.24 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 36 units (0.36 mL) |
Route: Subcutaneous | Frequency: Once daily Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 10 for better accuracy. Dosing is extrapolated from preclinical models[1][6]; human clinical validation remains limited.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support tissue-healing and recovery processes based on preclinical evidence[1][3].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 200–600 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 200 mcg daily; increase by ~200 mcg every 2 weeks as tolerated.
- Target: 400–600 mcg daily by Weeks 5–8+.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[10][11].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[8].
- Discard used syringes immediately in a sharps container per WHO guidelines[7].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (BPC-157, 5 mg each):
- 8 weeks ≈ 6 vials (25.2 mg used)
- 12 weeks ≈ 9 vials (42 mg used)
- 16 weeks ≈ 12 vials (58.8 mg used)
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 12 weeks (9 vials): 27 mL → 3 × 10 mL bottles
- 16 weeks (12 vials): 36 mL → 4 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 04
Research publication
Life Sciences — Seiwerth S et al. BPC-157 and standard angiogenic growth factors: gastrointestinal tract healing and beyond (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
HSS Journal (PubMed) — Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: systematic review (2025) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
Journal of Orthopaedic Research — Chang CH et al. BPC-157 promotes tendon-to-bone healing in a rat rotator cuff model (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
WHO (NCBI Bookshelf) — Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings (2016) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (patient education resource) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Research publication
World Journal of Gastroenterology (PMC) — Sikiric P et al. Pentadecapeptide BPC-157: from GI tract to whole body healing (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.